rolapitant trade name varubi vəˈruːbi vəroobee us varuby european union drug originally developed scheringplough licensed clinical development tesaro acts selective receptor antagonist antagonist approved medication treatment chemotherapyinduced nausea vomiting cinv clinical trials showed similar improved efficacy improvement safety existing drugs rolapitant used combination antiemetic antivomiting agents adults prevention delayed nausea vomiting associated initial repeat courses emetogenic cancer chemotherapy including limited highly emetogenic approved antiemetic combination consists rolapitant plus dexamethasone us approval rolapitant contraindicated combination thioridazine whose inactivation could inhibited european approval contraindicated combination st johns wort expected accelerate inactivation studies comparing chemotherapy plus rolapitant dexamethasone antagonist chemotherapy plus placebo dexamethasone antagonist side effects comparable frequencies groups differed chemotherapy regimens rolapitant placebo groups common side effects included decreased appetite rolapitant vs placebo neutropenia vs vs depending kind chemotherapy dizziness vs indigestion stomatitis vs eightfold therapeutic doses given studies without rolapitant moderately inhibits liver enzyme blood plasma concentrations substrate dextromethorphan increased threefold combined rolapitant increased concentrations substrates expected drug also inhibits transporter proteins breast cancer resistance protein bcrp pglycoprotein pgp shown increase plasma concentrations substrate sulfasalazine twofold pgp substrate digoxin strong inducers liver enzyme decrease area curve rolapitant active metabolite called rifampicin effect almost study inhibitors relevant effect rolapitant rolapitant active metabolite block receptor high affinity selectivity block closely related receptor tested receptors enzymes therapeutic concentrations rolapitant practically completely absorbed gut independently food intake undergoes measurable firstpass effect liver highest blood plasma concentrations reached four hours bloodstream substance bound plasma metabolized liver enzyme resulting major active metabolite rolapitant number inactive metabolites rolapitant mainly excreted via feces unchanged form lesser extent via urine form inactive metabolites elimination halflife seven days hours wide dosing drug used form rolapitant hydrochloride monohydrate white offwhite slightly hygroscopic crystalline powder maximum solubility aqueous solutions ph httpsenwikipediaorgwikirolapitant